Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma.
Adult
Aged
Carcinoma, Squamous Cell
/ radiotherapy
Drug Therapy, Combination
Female
Humans
Hyaluronic Acid
/ administration & dosage
Iran
Male
Middle Aged
Mouth Neoplasms
/ radiotherapy
Oral Sprays
Procollagen
/ administration & dosage
Prospective Studies
Radiation Injuries
/ drug therapy
Stomatitis
/ drug therapy
Treatment Outcome
Mucosamin
Oral Cavity Squamous Cell Carcinoma
Oral Mucositis
radiotherapy
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
04
12
2019
entrez:
28
11
2021
pubmed:
29
11
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Oral mucositis is a serious complication radiation therapy for cancer. This is a major complication during radiation therapy of the head and neck tumors in approximately all patients. Therefore, this study was conducted to evaluate the effect of Mucosamin on treatment of radiation induced oral mucositis during and after radiotherapy amongst patients with oral cavity squamous cell carcinoma. In this prospective clinical trial, eligible patients who referred to radiation oncology department of Namazi Hospital, Shiraz, Iran from Jan 2018 till Jan 2019 were evaluated. The cases with confirmed pathologic diagnosis of squamous cell carcinoma of the oral cavity underwent 6,000 cGy radiation therapy and were randomly divided into two groups: 1- Intervention group; Mucosamin spray for 3-4 times a day (n = 40); 2 - Control group; standard medications (3 times a day) (n = 40). Oral mucositis was evaluated weekly based on RTOG scoring scale. Grade of mucositis was recorded during treatment and after radiation therapy. A total of 80 patients were divided in two groups of Mucosamin and control. From week 3 until the end of radiotherapy (week 6) and after radiotherapy (week 8), there was a significant difference in the severity of oral mucositis between the Mucosamin and the control groups (P <0.05). The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Oral mucositis is a serious complication radiation therapy for cancer. This is a major complication during radiation therapy of the head and neck tumors in approximately all patients. Therefore, this study was conducted to evaluate the effect of Mucosamin on treatment of radiation induced oral mucositis during and after radiotherapy amongst patients with oral cavity squamous cell carcinoma.
MATERIALS AND METHODS
METHODS
In this prospective clinical trial, eligible patients who referred to radiation oncology department of Namazi Hospital, Shiraz, Iran from Jan 2018 till Jan 2019 were evaluated. The cases with confirmed pathologic diagnosis of squamous cell carcinoma of the oral cavity underwent 6,000 cGy radiation therapy and were randomly divided into two groups: 1- Intervention group; Mucosamin spray for 3-4 times a day (n = 40); 2 - Control group; standard medications (3 times a day) (n = 40). Oral mucositis was evaluated weekly based on RTOG scoring scale. Grade of mucositis was recorded during treatment and after radiation therapy.
RESULTS
RESULTS
A total of 80 patients were divided in two groups of Mucosamin and control. From week 3 until the end of radiotherapy (week 6) and after radiotherapy (week 8), there was a significant difference in the severity of oral mucositis between the Mucosamin and the control groups (P <0.05).
CONCLUSION
CONCLUSIONS
The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma.<br />.
Identifiants
pubmed: 34837931
doi: 10.31557/APJCP.2021.22.11.3711
pmc: PMC9068180
pii:
doi:
Substances chimiques
Oral Sprays
0
Procollagen
0
Hyaluronic Acid
9004-61-9
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3711-3715Références
Oral Dis. 2014 Apr;20(3):e7-18
pubmed: 24147592
Head Neck. 2011 Jun;33(6):774-9
pubmed: 20737496
Radiother Oncol. 2016 Jul;120(1):13-20
pubmed: 27113797
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1141-1152
pubmed: 31063799
Photomed Laser Surg. 2014 Jan;32(1):10-6
pubmed: 24328847
Eur J Oncol Nurs. 2018 Jun;34:89-97
pubmed: 29784145
Indian J Dent Res. 2012 Nov-Dec;23(6):843
pubmed: 23649087
Cochrane Database Syst Rev. 2015 Dec 23;(12):CD011552
pubmed: 26695736
J Biol Regul Homeost Agents. 2016 Jul-Sep;30(3):889-894
pubmed: 27655517
Clin Exp Dermatol. 2012 Jul;37(5):516-20
pubmed: 22632105
Medicine (Baltimore). 2017 Dec;96(50):e8446
pubmed: 29390253
Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):35-53
pubmed: 24287192
Open Dent J. 2012;6:126-30
pubmed: 22930665
Indian J Dent Res. 2010 Jul-Sep;21(3):316-9
pubmed: 20930335
Crit Rev Oncol Hematol. 2016 Apr;100:147-66
pubmed: 26947812
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Cancer Nurs. 2004 May-Jun;27(3):183-205
pubmed: 15238805
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):143-51
pubmed: 20378002